SynthesisEuropean respiratory review : an official journal of the European Respiratory Society2019
A systematic review of pharmacotherapeutic clinical trial end-points for bronchiectasis in adults.
Synthesis in European respiratory review : an official journal of the European Respiratory Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Inhaled tobramycin for chronic pseudomonas aeruginosa infection in non-cystic fibrosis bronchiectasis: an updated systematic review and meta-analysis.BMC pulmonary medicine · 2026Pooled it
- Endotypes ofAmerican journal of respiratory and critical care medicine · 2025Trial
- Patient-Reported Outcome scale for Bronchiectasis (BE-PRO): development and validation in China.Annals of medicine · 2026Article
- Treatable traits-based management of bronchiectasis: moving from theory to clinical practice.Chinese medical journal pulmonary and critical care medicine · 2026Review
- Association of German Bronchiectasis Registry participation with disease course.ERJ open research · 2026Article
- Multidimensional lung imaging: integrated preclinical platforms enabling the identification of translational biomarkers for pulmonary research.Respiratory research · 2026Review
- Bronchiectasis and sinonasal diseases: a narrative review.ERJ open research · 2025Review
- Multiple-breath washout is more sensitive than spirometry to detect lung function impairment in children and adults with bronchiectasis.ERJ open research · 2025Article
- The Precision Medicine Era of Bronchiectasis.American journal of respiratory and critical care medicine · 2024Article
- Exacerbations of bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Biomarkers in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Infection and the microbiome in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Clinimetric Properties of Outcome Measures in Bronchiectasis.Annals of the American Thoracic Society · 2023Article
- Clinical outcomes of bronchiectasis in India: data from the EMBARC/Respiratory Research Network of India registry.The European respiratory journal · 2023Observational
- Airway Inflammation in Children with Primary Ciliary Dyskinesia.Annals of the American Thoracic Society · 2023Observational
- Traction bronchiectasis: is it as benign as we think?Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2022Article
- ERS International Congress 2021: highlights from the Respiratory Infections Assembly.ERJ open research · 2022Review
- Efficacy of Roflumilast in Bronchiectasis Patients with Frequent Exacerbations: A Double-Blinded, Randomized, Placebo-Controlled Pilot Clinical Trial.Tuberculosis and respiratory diseases · 2022Article
- Integrative microbiomics in bronchiectasis exacerbations.Nature medicine · 2021Article
- Measuring airway clearance outcomes in bronchiectasis: a review.European respiratory review : an official journal of the European Respiratory Society · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bronchiectasis is an increasing clinical problem, but multiple recent clinical trials have failed to reach their primary end-point. Difficulties in achieving "positive" bronchiectasis trials is reflected in a lack of agreement from trialists and regulators on what are the optimal end-points.To evaluate the use of end-points in bronchiectasis trials, we conducted a systematic review of published bronchiectasis trials from 2008 to 2018 and extracted end-points used, definitions, methods of analysis and responsiveness.Our analysis shows that quality of life and exacerbation end-points are most frequently used. Trials using exacerbation end-points have been characterised by varying definitions, multiple methods of analysis and durations of follow-up. There are multiple quality of life tools for bronchiectasis (Quality of Life - Bronchiectasis questionnaire, St George's Respiratory Questionnaire,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.